Implications of the PEARL trial from the low- to middle-income countries' perspectives

Eur J Cancer. 2022 Sep:173:30-32. doi: 10.1016/j.ejca.2022.06.016. Epub 2022 Jul 13.

Authors

Tomás Reinert¹, Aline C Gonçalves², C A A de Resende³, Carlos H Barrios⁴

Affiliations

¹ Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Oncoclinicas, Porto Alegre, Brazil.
² Oncoclinicas, Rio de Janeiro, Brazil.
³ Oncoclinicas, Brasília, Brazil.
⁴ Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Oncoclinicas, Porto Alegre, Brazil. Electronic address: [email protected].

PMID: 35841844
DOI: 10.1016/j.ejca.2022.06.016

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols* / economics
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Breast Neoplasms* / drug therapy
Breast Neoplasms* / pathology
Capecitabine* / economics
Capecitabine* / therapeutic use
Developing Countries
Female
Health Care Costs*
Humans
Income

Substances

Capecitabine